2 Under-the-Radar Growth Stocks to Consider [Yahoo! Finance]
Madrigal Pharmaceuticals, Inc. (MDGL)
Last madrigal pharmaceuticals, inc. earnings: 2/26 06:50 am
Check Earnings Report
US:NASDAQ Investor Relations:
madrigalpharma.com
Company Research
Source: Yahoo! Finance
Mid-cap biotechs Madrigal Pharmaceuticals (NASDAQ: MDGL) and Axsome Therapeutics (NASDAQ: AXSM) seem to fit the bill. Both drugmakers look highly promising, and there could be plenty of upside at their current market values. Let's find out more. 1. Madrigal Pharmaceuticals Madrigal Pharmaceuticals recently earned approval from the U.S. Food and Drug Administration (FDA) for Rezdiffra, the first therapy on the market for non-alcoholic steatohepatitis (NASH), a severe liver disease affecting about 5% of adults in the U.S., according to some estimates. Though plenty of pharmaceutical giants with much bigger budgets tried to develop therapies for NASH, Madrigal -- a small-cap biotech -- beat them all to the punch. And patients will have access to Rezdiffra without needing a liver biopsy first, a requirement that would have limited its sales potential. The company will target a market of roughly 315,000 patients. Rezdiffra will almost certainly exceed $1 billion in annual sales at
Show less
Read more
Impact Snapshot
Event Time:
MDGL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MDGL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MDGL alerts
High impacting Madrigal Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
MDGL
News
- Madrigal Statement on the Passing of Dr. Stephen HarrisonGlobeNewswire
- Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage [Seeking Alpha]Seeking Alpha
- Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024 [Yahoo! Finance]Yahoo! Finance
- Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024GlobeNewswire
- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is now covered by analysts at Bank of America Co.. They set an "underperform" rating and a $150.00 price target on the stock.MarketBeat